SRRK · Scholar Rock Holding Corp

Scholar Rock Holding Corp Is A Biopharmaceutical Company Focused On Improving The Lives Of Children And Adults With Spinal Muscular Atrophy And Other Rare, Severe, And Debilitating Neuromuscular Diseases. Its Pipeline Candidates Include Apitegromab And A Subcutaneous Formulation Of Apitegromab. The Clinical-Stage Pipeline Also Includes Srk-439, An Investigational Subcutaneously Administered Fully Human Anti-Pro/Latent Myostatin Antibody With High Inhibitory Potency And Selectivity Toward Myostatin, Being Developed For The Treatment Of Rare Neuromuscular Diseases. The Company Also Maintains Early-Stage Programs Focused On Therapies For Rare, Severe, And Debilitating Neuromuscular Diseases.